Skip to main content
    B

    Beta Bionics, Inc. Common Stock (BBNX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $15.21
    -1.21 (-7.37%)

    Market Cap: $892.71M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Beta Bionics, Inc. Common Stock (BBNX) Financials: Revenue, Profit and Cash Flow

    Updated Oct 27, 2026. Financial statements from company filings, amounts in US dollars.

    Beta Bionics, Inc. Common Stock reported revenue of $100.25M for the fiscal year ended Dec 31, 2025, up 53.9% from the year before. That year, net income was -$73.20M with a net margin of -73.0%, operating cash flow was -$50.92M and free cash flow was -$56.22M. The quarter ended Sep 30, 2026 had revenue of $35.51M and net income of -$24.35M.

    Revenue and Margins

    The operating margin was -71.5% in the fiscal year ended Dec 2025.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$100.25M+53.9%55.4%-71.5%-73.0%
    Dec 2024$65.12M+442.9%55.1%-69.5%-84.1%
    Dec 2023$11.99M+6601.1%52.6%-298.9%-367.6%
    Dec 2022$179.00KN/A100.0%-36784.4%-36173.7%
    Annual, fiscal years ended Dec 2022 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022
    Revenue$100.25M$65.12M$11.99M$179.00K
    Cost of revenue$44.71M$29.24M$5.69MN/A
    Gross profit$55.54M$35.89M$6.31M$179.00K
    Research and development$34.79M$26.18M$17.94M$31.43M
    Operating income-$71.68M-$45.25M-$35.85M-$65.84M
    Net income-$73.20M-$54.76M-$44.10M-$64.75M
    EBITDAN/AN/AN/A-$63.40M
    Fiscal years ended Dec 2022 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$35.51M$32.01M$27.63M$32.12M$27.25M$23.24M$17.64M$20.44M$16.70M$15.05M$12.93M$8.35M
    Gross profit$20.33M$18.90M$16.44M$18.94M$15.12M$12.50M$8.97M$11.69M$8.91M$8.08M$7.20M$5.06M
    Operating income-$26.61M-$25.58M-$24.27M-$16.12M-$17.04M-$19.87M-$18.64M-$13.04M-$10.98M-$11.78M-$9.45M-$8.37M
    Net income-$24.35M-$23.40M-$21.89M-$13.47M-$14.21M-$16.87M-$28.66M-$18.11M-$9.74M-$14.46M-$12.45M-$18.85M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.94M by $29.64M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022
    Total assets$328.74M$149.65M$110.04M$35.53M
    Current assets$267.90M$132.92M$103.62M$28.47M
    Cash and equivalents$31.58M$30.43M$26.57M$27.68M
    Total liabilities$41.13M$73.63M$51.43M$22.53M
    Short-term debt$1.94M$1.53M$1.22M$976.00K
    Shareholder equity$287.61M-$245.36M-$203.10M$13.00M
    Fiscal years ended Dec 2022 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$443.76M$292.39M$304.42M$328.74M$330.05M$329.97M$338.02M$149.65M$96.94MN/AN/A$110.04M
    Total liabilities$42.38M$36.02M$33.17M$41.13M$35.29M$28.34M$24.27M$73.63M$64.07MN/A-$58.61M$51.43M
    Cash and equivalents$81.55M$44.32M$30.21M$31.58M$38.48M$35.08M$42.45M$30.43M$17.48MN/A$96.75M$26.57M
    Shareholder equity$401.38M$256.37M$271.25M$287.61M$294.76M$301.63M$313.75M$76.01M$32.87MN/A$58.61M$58.61M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022
    Operating cash flow-$50.92M-$48.27M-$32.45M-$60.21M
    Capital expenditures$5.30M$3.40M$402.00K$772.00K
    Free cash flow-$56.22M-$51.67M-$32.85M-$60.98M
    Share repurchases$0$4.15M$0N/A
    Investing cash flow-$162.81M-$3.48M-$69.69M-$769.00K
    Financing cash flow$214.87M$55.62M$101.03M$56.78M
    Fiscal years ended Dec 2022 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$12.29M-$14.62M-$23.83M-$8.63M-$8.73M-$13.59M-$19.98M-$14.28M-$9.61M-$12.24M-$12.14M-$6.35M
    Capital expenditures$2.27M$1.04M$1.38M$1.90M$1.28M$1.78M$333.00K$561.00K$1.92M$507.00K$406.00K$313.00K
    Free cash flow-$14.56M-$15.66M-$25.21M-$10.53M-$10.01M-$15.37M-$20.31M-$14.84M-$11.53M-$12.74M-$12.55M-$6.66M
    Last 12 quarters

    Frequently Asked Questions About BBNX

    What is Beta Bionics, Inc. Common Stock's annual revenue?

    Beta Bionics, Inc. Common Stock reported revenue of $100.25M for the fiscal year ended Dec 31, 2025.

    How fast is Beta Bionics, Inc. Common Stock's revenue growing?

    Revenue was up 53.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 724.3%.

    Is Beta Bionics, Inc. Common Stock profitable?

    No. Beta Bionics, Inc. Common Stock reported net income of -$73.20M for the fiscal year ended Dec 31, 2025, with a net margin of -73.0%.

    How much free cash flow does BBNX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$50.92M minus capital expenditures of $5.30M produced free cash flow of -$56.22M.

    How much debt does Beta Bionics, Inc. Common Stock have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.94M and cash and equivalents of $31.58M.